We want to save millions of lives by predicting cancer and enable personalized care through a reliable early diagnosis of Lynch Syndrome.

LS CancerDiag

21 December 2019

Helsinki, Finland

Press Release – LS CancerDiag strengthens the management team in 2019

The last year of this decade has been a very successful one for LS CancerDiag, where many important milestones were achieved, and the basis was laid for strong growth over the coming years. To gear up for a promising 2020, LS CancerDiag has strengthened its management team to take the next step towards its ambitious vision to make DiagMMR® the Gold standard for Lynch syndrome detection.

LS CancerDiag has appointed Philippe Arnez from Switzerland in the position of Chief Business Officer, effective 1 July 2019. Philippe brings a wealth of experience from corporate roles in major blue-chip companies on an international level in Europe and the Americas, with responsibilities for strategy development, change management, procurement and logistics. At LS CancerDiag he is responsible for commercial partnerships, international expansion, marketing & communications, and strategic planning.

Dr. Minttu Kansikas has been appointed as Chief Scientific Officer to lead the research efforts and laboratory functions. Minttu is a co-inventor and one of the leading scientists behind the cancer predictive DiagMMR® testing. She has over 10 years of experience in Lynch syndrome and DNA repair research activities. Minttu has been with LS CancerDiag from the very beginning, latest in the role of R&D director, and is a key contributor to the successes the company has achieved so far. She will certainly continue to do so as she takes on the responsibility for our laboratory functions and research & development activities.

Minttu and Philippe join Niklas Lahti, Chief Financial Officer since 2017, in the management team to lead the company into the next decade under the leadership of Founder and CEO Prof. Minna Nyström.

About LS CancerDiag Ltd

LS CancerDiag is committed to reducing cancer mortality rates with a simple and accurate diagnostic method that detects an inherited cancer-causing condition prior to cancer and enables preventive and personalized care. Lynch syndrome (previously known as Hereditary Non-Polyposis Colorectal Cancer; HNPCC) is the main cause of hereditary colorectal cancers, but it is also linked to endometrial cancer and various other types of tumors. With its high prevalence in the world's population and the currently very low diagnosis rates, there are millions of people with Lynch syndrome without being aware of it. The groundbreaking DiagMMR® assay is an easy functional test that can be used for diagnosis of MMR deficiency, the key characteristic of Lynch syndrome. The company mission is to save lives through an innovation that dramatically simplifies diagnostics of Lynch syndrome by delivering predictive and accurate results globally with a fast, unique and cost-efficient method.

Contact information
Philippe Arnez, Chief Business Officer
philippe.arnez@lscancerdiag.com

LS CancerDiag Ltd
@LSCancerDiag
http://www.lscancerdiag.com